What is the appropriate management for a flare of paroxysmal nocturnal hemoglobinuria (PNH)?

Management of Paroxysmal Nocturnal Hemoglobinuria (PNH) Flare

For acute hemolytic flares in PNH patients, immediately assess severity and initiate supportive care with red blood cell transfusions targeting hemoglobin 7-8 g/dL, while urgently evaluating for complement inhibitor therapy (eculizumab, ravulizumab, or crovalimab) in patients with severe hemolysis or thrombotic complications. 1

Immediate Assessment and Supportive Management

When a PNH patient presents with a hemolytic flare, obtain the following laboratory tests urgently:

• Complete blood count with peripheral smear to assess degree of anemia and presence of hemolysis 1
• Hemolysis markers: elevated LDH, low haptoglobin, elevated indirect bilirubin, elevated reticulocyte count 1
• Renal function tests and urinalysis for hemoglobinuria 1
• Complement testing (C3, C4, CH50) to evaluate complement activity 1

Provide red blood cell transfusions only to relieve symptoms or achieve hemoglobin 7-8 g/dL in stable patients, avoiding over-transfusion which can suppress endogenous erythropoiesis 1, 2. Use leukoreduced blood products to minimize alloimmunization 2.

Folic Acid Supplementation

Administer folic acid 1 mg daily to support erythropoiesis in all PNH patients with active hemolysis 1.

Complement Inhibitor Therapy for Severe Hemolysis

For patients with severe hemolysis (Grade 3-4) or thrombotic complications, initiate complement inhibitor therapy immediately 1:

First-Line C5 Inhibitor Options:

• Eculizumab: 900 mg IV weekly for 3-4 doses, then 1200 mg at week 5, followed by 1200 mg every 2 weeks 1
• Ravulizumab: IV every 8 weeks (provides longer dosing intervals with similar efficacy) 3
• Crovalimab: subcutaneous every 4 weeks (most convenient administration) 3

Before initiating any complement inhibitor, ensure meningococcal vaccination and provide long-term penicillin prophylaxis to prevent life-threatening infections 4.

Management of Breakthrough Hemolysis on C5 Inhibitors

Approximately 30% of patients on C5 inhibitors develop clinically significant extravascular hemolysis with ongoing transfusion requirements or symptomatic anemia 3. If breakthrough hemolysis occurs despite C5 inhibition:

Consider Switching to Proximal Complement Inhibitors:

• Iptacopan (factor B inhibitor): 200 mg orally twice daily, which addresses both intravascular and extravascular hemolysis 5, 3
• Pegcetacoplan (C3 inhibitor): subcutaneous twice weekly as monotherapy 3
• Danicopan (factor D inhibitor): oral three times daily as add-on to eculizumab or ravulizumab 3

When switching from crovalimab to iptacopan, wait approximately three weeks after the final crovalimab dose before initiating iptacopan 5. Hemoglobin improvement typically occurs within two weeks of switching, with clinical symptoms resolving within one week 5.

Anticoagulation for Thrombotic Events

For patients with prior thrombotic events, initiate anticoagulation therapy, as thrombosis risk persists even on eculizumab 1. The duration should be indefinite given the ongoing prothrombotic state in PNH 6.

Monitoring During Acute Flare

Monitor the following parameters closely:

• Hemoglobin and reticulocyte count to assess response 1
• Surveillance for breakthrough hemolysis signs: dark urine, fatigue, abdominal pain 1
• LDH, haptoglobin, and bilirubin to gauge treatment response 2
• Platelet counts to monitor for thrombotic risk 4

Critical Pitfalls to Avoid

Do not delay complement inhibitor therapy in patients with severe hemolysis or thrombosis, as mortality increases with delayed treatment 2. The presence of smooth muscle dystonia symptoms (abdominal pain, dysphagia, erectile dysfunction) indicates severe intravascular hemolysis requiring urgent intervention 7.

Do not over-transfuse beyond hemoglobin 7-8 g/dL in stable patients, as this suppresses endogenous erythropoiesis and increases alloimmunization risk 1, 2.

Recognize that breakthrough hemolysis can occur with any complement inhibitor during strong complement triggers (such as infections), but may be more severe with alternative pathway inhibitor monotherapy 3, 8. Infectious enteritis is a known trigger for breakthrough hemolysis 5.

Iron Replacement

Provide iron supplementation (oral or IV) for iron deficiency resulting from chronic hemoglobinuria 1. Monitor ferritin levels regularly in transfusion-dependent patients and consider liver MRI to assess iron deposition in those with chronic transfusion requirements 2.